Efficacy and safety of osimertinib plus anlotinib in advanced non-small-cell lung cancer patients after drug resistance.
Thoracic cancer（2023）
摘要
Osimertinib combined with anlotinib as three or more lines of treatment in advanced NSCLC was effective and adverse events were tolerable.
更多查看译文
关键词
anlotinib,drug resistance,non-small-cell lung cancer,osimertinib,targeted therapy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要